UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended April 3, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State or other jurisdiction of incorporat ...

being recorded. If anyone has any objections, you may disconnect at this time. We continue to deliver reliable growth and generate meaningful free cash flow, enabling us to invest and advance our pipeline, increase our dividend for the 60th consecutive year, and continue to make a positive impact across the landscape of healthcare. It is, however, important to take a few moments to recognize the current events that are impacting the world we're living in. Today, while we're all still managing through the gl ...

Business Segments - The company is organized into three business segments: Consumer Health, Pharmaceutical, and Medical Devices[12] - The Consumer Health segment includes major brands such as AVEENO, NEUTROGENA, and TYLENOL, with a planned separation to create a new publicly traded company targeted for completion in 18 to 24 months[13] - The Pharmaceutical segment focuses on six therapeutic areas, including Immunology and Oncology, with key products like REMICADE and STELARA[14] - The Medical Devices segment, referred to as the MedTech segment, includes a broad range of products across various fields such as Interventional Solutions and Orthopaedics[16] - The Medical Devices segment will be referred to as the MedTech segment starting in the fiscal first quarter of 2022[16] Financial Performance - Sales of the Company's largest product, STELARA, accounted for approximately 9.7% of total revenues for fiscal 2021[21] - Sales of the second largest product, DARZALEX and DARZALEX FASPRO, accounted for approximately 6.4% of total revenues for fiscal 2021[21] - The company anticipates challenges in product development and market success due to competition and regulatory approvals[9] - Pricing pressures are expected from healthcare cost containment trends and consolidation among healthcare providers[10] - Economic conditions and global operations may affect the company's financial performance and market position[10] - The Company faces patent challenges from third parties regarding key pharmaceutical products, which may impact financial results[19] Regulatory and Compliance - The company emphasizes the importance of compliance with regulatory requirements and potential changes in laws affecting operations[10] - The Company is subject to increasing regulatory scrutiny, which may impact its financial condition and business operations[26] - The Company is subject to increasingly stringent governmental regulations, which may adversely affect financial condition and business operations[26] - The company is subject to increased scrutiny from government agencies regarding business practices, which may lead to significant civil and criminal penalties[29] Supply Chain and Risks - The company faces risks related to supply chain disruptions and manufacturing delays that could impact product availability[10] - The Company is addressing risks associated with patent expirations and competition from generic products[9] Human Capital Management - The Company employs approximately 141,700 full-time equivalent positions as of 2021, an increase from 134,500 in 2020[30] - In 2021, 91% of global employees participated in the Our Voice Survey, providing feedback on the Company's culture and engagement[31] - The Company focuses on attracting, developing, and retaining talent as part of its human capital management strategy[30] - In 2021, 45.8% of employees in Manager and above job categories utilized career opportunities through lateral transfers or promotions[33] - The Company's voluntary turnover rate was 8%[33] - The Company is focused on attracting and retaining top talent through professional development programs[33] Employee Health and Well-being - The Company has expanded health and well-being programs globally, incorporating new technologies to support employee health goals[36] - The Company is committed to competitive compensation and benefits, exceeding legal minimum wage provisions[35] - The Company’s total rewards offerings include performance incentives, retirement savings programs, and mental health support[35] - The Company emphasizes the importance of employee health and safety, especially during the COVID-19 pandemic[37] - The company has adopted policies requiring proof of COVID-19 vaccination for employees and contingent workers in the U.S. and Puerto Rico, effective October 4, 2021[37] Diversity, Equity, and Inclusion - The Company’s DEI strategy focuses on building a diverse workforce and enhancing business results[34] - The company focuses on diversity, equity, and inclusion (DEI) with a strategy that includes building a diverse workforce and enhancing business results[34] Growth Strategies - Forward-looking statements indicate potential growth strategies, including acquisitions and product development initiatives[7] - The Company is evaluating flexible work strategies for its on-site workforce to support work-life balance[37] - The company has implemented a hybrid work model, J&J Flex, which began rolling out globally in Q4 2021, allowing for a balance of in-person and remote work[37]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 27, 2020 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 | --- | --- | |------------------------------------------------------------------------------------------|------------------------------------------| | | | | for the transition period from | to | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 28, 2020 or | --- | --- | |------------------------------------------------------------------------------------------------------|---------------------------------------------------------| | | | | Transition Report Pursuant to Section 13 or 15(d) of for the transition period | the Securities Exchange Ac ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 29, 2020 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State or other jurisdiction of incorpora ...